Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial

Published:2021-04 Issue:4 Volume:8 Page:e267-e277
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Frontzek Fabian,Ziepert Marita,Nickelsen Maike,Altmann Bettina,Glass Bertram,Haenel Mathias,Truemper Lorenz,Held Gerhard,Bentz Martin,Borchmann Peter,Dreyling Martin,Viardot Andreas,Kroschinsky Frank P,Metzner Bernd,Staiger Annette M,Horn Heike,Ott German,Rosenwald Andreas,Loeffler Markus,Lenz Georg,Schmitz Norbert

Funder

Deutsche Krebshilfe

Publisher

Elsevier BV

Subject

Hematology

Reference37 articles.

1. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles;Cunningham;Lancet,2013

2. A predictive model for aggressive non-Hodgkin's lymphoma;N Engl J Med,1993

3. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI;Ruppert;Blood,2020

4. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab;Barrans;J Clin Oncol,2010

5. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium;Rosenwald;J Clin Oncol,2019

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of overall survival benefit of radiotherapy with progression-free survival after chemotherapy for diffuse large B-cell lymphoma: A systematic review and meta-analysis;Journal of the National Cancer Center;2024-09

2. Management of High-Grade B-Cell Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP;Blood Advances;2024-04-28

4. Radiotherapy in younger patients with advanced aggressive B-cell lymphoma—long-term results from the phase 3 R-MegaCHOEP trial;Leukemia;2024-03-27

5. Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study;HemaSphere;2024-03